anti PD-L1 mAb
/ Sutro Biopharma, BMS
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 08, 2020
Defining Resistance to Treatment with Anti-PD-1/PD-L1 Immunotherapy
- "In order to address this unmet need, the Society for Immunotherapy of Cancer (SITC) convened experts from academia, industry, and government to define PD-1/PD-L1 resistance via three categories: primary resistance, secondary resistance, and progression after treatment discontinuation....collectively defined each resistance classification, timeframes that delineate each resistance type, and methods to confirm resistance.....Additional CRI scientists involved in this effort included...Dung T. Le, M.D..."
1 to 1
Of
1
Go to page
1